News
![](https://cdn-uat.mdedge.com/files/s3fs-public/styles/max_width_small/public/Powles_Thomas_UK_web.jpg)
Enfortumab vedotin shows promise as new option for urothelial carcinoma
- Author:
- Susan London
The antibody-drug conjugate outperformed chemotherapy in patients with previously treated locally advanced or...
News
![](https://cdn-uat.mdedge.com/files/s3fs-public/styles/max_width_small/public/Huddart_Robert_A_LONDON_web.jpg)
Surveillance after testicular cancer: New approaches slash radiation exposure
- Author:
- Susan London
In TRISST three more widely spaced scans were noninferior to the standard schedule of seven scans; also, MRI...
News
![](https://cdn-uat.mdedge.com/files/s3fs-public/styles/max_width_small/public/Motzer_Robert_J_NY_2021_web.jpg)
Combo delivers ‘impressive’ survival results in first-line RCC setting
- Author:
- Susan London
Lenvatinib plus pembrolizumab improved progression-free and overall survival, compared with single-agent sunitinib.
News
![](https://cdn-uat.mdedge.com/files/s3fs-public/styles/max_width_small/public/Pal_Sumantha_CA_web.jpg)
Cabozantinib could be new standard for papillary RCC
- Author:
- Susan London
Compared with sunitinib, cabozantinib prolonged progression-free survival in patients with metastatic disease.
News
![](https://cdn-uat.mdedge.com/files/s3fs-public/styles/max_width_small/public/Bajorin_Dean_NY_web.jpg)
Adjuvant nivolumab: A new standard of care in high-risk MIUC?
- Author:
- Susan London
Nivolumab nearly doubled disease-free survival when compared with placebo.
News
![](https://cdn-uat.mdedge.com/files/s3fs-public/styles/max_width_small/public/Rathkopf_Dana_NY_web.jpg)
Androgen annihilation strategy prolongs rPFS in mCRPC
- Author:
- Susan London
Adding apalutamide to abiraterone and prednisone prolonged radiographic progression-free survival by 7.4 months.
News
![](https://cdn-uat.mdedge.com/files/s3fs-public/styles/max_width_small/public/Quillen_Michael_FL_web.jpg)
EHR data harnessed to spot new risk factors for early-onset CRC
- Author:
- Susan London
Machine learning models indicated that hypertension, cough, asthma, and other factors, were important in determining the risk of early-onset...
News
![](https://qa00.mdedge.com/sites/all/modules/contrib/lazyloader/image_placeholder.gif)
Test could help patients with pancreatic cysts avoid unneeded surgery
- Author:
- Susan London
The test proved more accurate than the current standard of care.
News
![](https://cdn-uat.mdedge.com/files/s3fs-public/styles/max_width_small/public/Scanlon_Lauren_A_UK_web.jpg)
Model predicts acute kidney injury in cancer patients a month in advance
- Author:
- Susan London
A machine learning algorithm identified nearly three-quarters of patients who went on to develop acute kidney injury.
News
![](https://qa00.mdedge.com/sites/all/modules/contrib/lazyloader/image_placeholder.gif)
Test could help patients with pancreatic cysts avoid unneeded surgery
- Author:
- Susan London
The test proved more accurate than the current standard of care.
News
![](https://cdn-uat.mdedge.com/files/s3fs-public/styles/max_width_small/public/Wei_Mu_FL_web.jpg)
AI can identify biomarkers and potentially guide therapy in NSCLC
- Author:
- Susan London
Deep learning models accurately predicted PD-L1 positivity and EGFR mutational status in patients with non–small cell lung cancer.
News
![](https://cdn-uat.mdedge.com/files/s3fs-public/styles/max_width_small/public/Harbeck_Nadia_GERMANY1_web.jpg)
Adaptive biomarker approach may spare some breast cancer patients chemo
- Author:
- Susan London
The combination of recurrence score and Ki-67 response to a short preoperative course of endocrine therapy identified patients who could...
News
![](https://cdn-uat.mdedge.com/files/s3fs-public/styles/max_width_small/public/Murthy_Vedang_India_web.jpg)
POP-RT trial supports whole-pelvis radiotherapy for high-risk prostate cancer
- Author:
- Susan London
Prospective, randomized data suggest prophylactic whole-pelvis radiotherapy improves cancer outcomes without much increase in late toxicity.
News
![](https://cdn-uat.mdedge.com/files/s3fs-public/styles/max_width_small/public/Haviland_Joanne_UK_web.jpg)
One-week radiotherapy course should be standard for early invasive breast cancer, experts say
- Author:
- Susan London
Two 1-week adjuvant radiotherapy regimens for breast cancer are as effective as the standard 3-week regimen, the FAST-Forward trial suggests.
News
![](https://cdn-uat.mdedge.com/files/s3fs-public/styles/max_width_small/public/Potter_Richard_VIENNA_web.jpg)
‘Impressive’ local control with MRI-guided brachytherapy in cervical cancer
- Author:
- Susan London
Efficacy was poorer in node-positive and high-risk patients.